Liting Zhai
Research assistant professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2026
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Although blocking the binding of vascular endothelial growth factor (VEGF) to neuropilin-2 (NRP2) on tumor cells is a potential strategy to treat aggressive carcinomas, a lack of effective reagents that can be used clinically has hampered this potential therapy. Here, we describe the generation of a fully humanized, high-affinity monoclonal antibody (aNRP2-10) that specifically inhibits the binding of VEGF to NRP2, conferring antitumor activity without causing toxicity. Using triple-negative breast cancer as a model, we demonstrated that aNRP2-10 could be used to isolate cancer stem cells (CSCs) from heterogeneous tumor populations and inhibit CSC function and epithelial-to-mesenchymal transition. aNRP2-10 sensitized cell lines, organoids, and xenografts to chemotherapy and inhibited metastasis by promoting the differentiation of CSCs to a state that is more responsive to chemotherapy and less prone to metastasis. These data provide justification for the initiation of clinical trials designed to improve the response of patients with aggressive tumors to chemotherapy using this monoclonal antibody.
Year:
2023
Collaborators (6)
Thibault Viennet
Assistant Professor
Aarhus University
Ayush Kumar
University of Massachusetts Chan Medical School
Arthur M. Mercurio
Professor and Vice Chair
University of Massachusetts Chan Medical School
Laura Dassama
Assistant Professor
Stanford University
Yu Tang
University of California, Berkeley
Paula Welander
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.